The SONIA trial: redefining “better” in the sequencing of CDK4/6 inhibitors for advanced breast cancer
Qinghua Ke, Xiaohong Xie, Shiqiong Zhou · 2026
Read The SONIA trial: redefining “better” in the sequencing of CDK4/6 inhibitors for advanced breast cancer by Qinghua Ke, Xiaohong Xie, Shiqiong Zhou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13180554.txt.
Description
Qinghua Ke, Xiaohong Xie, and Shiqiong Zhou wrote a commentary, published in 2026, on the SONIA trial in advanced breast cancer. The trial tested drugs called CDK4/6 inhibitors, used for a common hormone-driven form of the disease. It asked whether starting these drugs at once works better than waiting until a later line of care.
Later results showed no gap in overall survival between the two plans, even though early use delayed the need for more treatment. The authors stress that the trial was not built to prove the two plans equal. They argue that 'better' care should weigh survival, side effects, and time on drugs, not just how long a scan stays stable. Their piece invites doctors to rethink the habit of using strong drugs as early as possible.
Catalog record
| CREATOR | Qinghua Ke, Xiaohong Xie, Shiqiong Zhou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |